Does folic acid have effects on other health problems than neural tube defects?;Effekt av folat på andre helseproblemer enn nevralrø rsdefekter?

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 4, 2005, Pages 438-441

  Staff, Anne Cathrine ^a   Holven, Kirsten ^b   Løken, Elin Bjørge ^b   Sygnestveit, Kari ^c   Vollset, Stein Emil ^d   Smeland, Sigbjørn ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Sosial og Helsedirektoratet ^*  (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID;

CANCER; CARDIOVASCULAR DISEASE; CONCEPTION; DIET SUPPLEMENTATION; FEMALE; FEMALE FERTILITY; HEALTH STATUS; HUMAN; MORBIDITY; MORTALITY; NEURAL TUBE DEFECT; NORWAY; PREGNANCY; REVIEW; RISK ASSESSMENT; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; INTERVENTION STUDY; NEOPLASM;

CARDIOVASCULAR DISEASES; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HUMANS; INTERVENTION STUDIES; NEOPLASMS; NEURAL TUBE DEFECTS; PREGNANCY;

EID: 14244267533     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Staff AC, Løken EB, Holven KB et al. Effekt av offentlige tiltak for å forebygge nevralrørsdefekter med folat. Tidsskr Nor Lægeforen 2005; 125 435-7.
2. Smeland S, Holven KB, Løken EB et al. Helsemessige gevinster av økt folatinntak? Hvordan nå ut til ønsket målgruppe. Rapport nr. 1, IS-1181. Oslo: Nasjonalt råd for ernæring, 2004.
3. Botten G, Gedde-Dahl S, Harby S et al. Anbefalinger og virkemidler for økt folatinntak blant kvinner i fertil alder. Rapport nr. 1, IS-1181. Oslo: Statens ernæringsråd, 1998.
4. Tell GS, Vollset SE, Jacobsen BK et al. Vurdering av behovet for økt folatinntak. Rapport nr. 2. Oslo: Statens ernæringsråd, 1997.
5. Goelz SE, Vogelstein B, Hamilton SR et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985; 228: 187-90.
6. Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56: 2463-7.
7. Blount BC, Mack MM, Wehr CM et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997; 94: 3290-5.
8. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Washington, D.C.: American Institute for Cancer Research, 1997.
9. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
10. Bautista LE, Arenas IA, Penuela A et al. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 2002; 55: 882-7.
11. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80: 874-7.
12. Kelly PJ, Rosand J, Kistler JP et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59: 529-36.
13. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-6.
14. Ueland PM, Hustad S, Schneede J et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201.
15. Vermeulen EG, Stehouwer CD, Twisk JW et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355: 517-22.
16. Schnyder G, Roffi M, Flammer Y et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002; 288: 973-9.
17. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 1998; 351: 263.
18. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345; 1593-1600.
19. Lange H, Suryapranata H, De Luca G et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350: 2673-81.
20. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH et al. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003; 41: 2105-13.
21. Liem AH, van Boven AJ, Veeger NJ et al. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 2004; 93: 175-9.
22. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
23. Woo KS, Chook P, Lolin YI et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-4.
24. Tawakol A, Omland T, Gerhard M et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
25. Chambers JC, McGregor A, Jean-Marie J et al. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998; 351: 36-7.
26. Bellamy MF, McDowell IF, Ramsey MW et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-52.
27. Woo KS, Chook P, Lolin YI et al. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-6.
28. Wilmink HW, Stroes ES, Erkelens WD et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000; 20: 185-8.
29. Usui M, Matsuoka H, Miyazaki H et al. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Lond) 1999; 96: 235-9.